Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

Shares of Zenas BioPharma (NASDAQ:ZBIO) rose on Thursday after Wedbush launched the newly IPO’ed biotech's coverage with an ...

Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.

Anti-C1q antibodies are highly prevalent among patients with IgG4-RD, particularly those with renal and skin manifestations.

Thalidomide demonstrated superior efficacy in preventing the relapse of immunoglobulin G4–related disease (IgG4-RD) during a 12-month follow-up period in a placebo-controlled trial. The ...

As previously reported, Wedbush initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $35 price target The firm notes its ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial. Just 10% of ...

The company is now waiting for the results of the INDIGO trial in IgG4-RD in 2025, aiming to become the first FDA-approved treatment for the progressive, fibroinflammatory disease, which can cause ...

Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV Technologies increased from 12 months through 60 months, according to an abstract ...

The systemic disease of which AIP is a part has been called IgG4-related systemic diseases. AIP mimics pancreatic cancer and it is critically important to distinguish between the two diseases.